Sub Subramony, M.D., discusses how the progression of patients' conditions often leads to a decline in quality of life and functional capabilities, highlighting key clinical indicators that necessitate the adoption of mobility aids.
Video content above is prompted by the following:
Can you shed light on the trajectory of patients’ quality of life, functional capabilities, and overall well-being as the condition advances, and how do you typically discern indications in clinical settings that signal a decline in ambulation necessitating the adoption of mobility aids?
Quantitative Magnetic Resonance Outcomes Suggest Gene Therapy Slows DMD Progression
May 14th 2025Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients with Duchenne muscular dystrophy (DMD) based on muscle quantitative magnetic resonance measures.
Read More
Coming Together to Ensure Neurological Treatment Access: Q&A With Kavita V. Nair, PhD
March 12th 2025In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Kavita V. Nair, PhD, of the University of Colorado Anschutz Medical Campus.
Read More